


AS can involve a severe inflammatory response and drastic changes in bone.^{21,24}
How does inflammation lead to manifestation?



A comprehensive look at what happens throughout the course of AS at the clinical presentation, bone, and cytokine levels.

Now available on the  App Store® and  Google Play for smartphones and tablets.

References: 1. Garg N, et al. *Best Pract Res Clin Rheumatol.* 2014;28(5):663-672. 2. Kiltz U, et al. *Clin Exp Rheumatol.* 2017;35(5):S102-S107. 3. Molto A, Sieper J. *Best Pract Res Clin Rheumatol.* 2018;32(3):357-368. 4. Rudwaleit M, et al. *Ann Rheum Dis.* 2011;70(1):25-31. 5. Deodhar A. Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis. *The Rheumatologist.* May 2014. 6. Deodhar A, et al. *Ann Rheum Dis.* 2016;75(5):791-794. 7. Lockwood MM, Gensler LS. *Best Pract Res Clin Rheumatol.* 2017;31(6):816-829. 8. Sieper J, Poddubnyy D. *Lancet.* 2017;390(10089):73-84. 9. Poddubnyy D, Sieper J. *Curr Opin Rheumatol.* 2014;26(4):377-383. 10. International Genetics of Ankylosing Spondylitis Consortium (IGAS). *Nat Genet.* 2013;45(7):730-738. 11. Sieper J, et al. *Nat Rev Dis Prim.* 2015;1(1):15013. 12. Liu M. Final Report: Characterizing the Patients with Axial Spondylarthritis in the Corrona PsA/SpA Registry. 2018. 13. Chung HY, et al. *Ann Rheum Dis.* 2011;70(11):1930-1936. 14. Swinnen TW, et al. *Arthritis Res Ther.* 2018;20(1):156. 15. de Winter JJ, et al. *Arthritis Res Ther.* 2016;18:196. 16. Wang R, et al. *Arthritis Rheumatol (Hoboken, NJ).* 2016;68(6):1415-1421. 17. Rusman T, et al. *Curr Rheumatol Rep.* 2018;20(6):35. 18. Mease PJ, et al. *Arthritis Care Res.* 2018;70(11):1661-1670. 19. Poddubnyy D, Gensler LS. *Best Pract Res Clin Rheumatol.* 2014;28(5):807-818. 20. Deodhar A, et al. *Arthritis Rheumatol.* 2019;71(7):1101-1111. 21. Malaviya AN, et al. *Int J Rheumatol.* 2017;2017:1-9. 22. Ortolan A, et al. *Arthritis Res Ther.* 2018;20(1):1-8. 23. Strand V, Singh JA. *J Clin Rheumatol.* 2017;23(7):383-391. 24. Feld J, et al. *Nat Rev Rheumatol.* 2018;14(6):363-371.

AS, ankylosing spondylitis; **ASAS**, Assessment of SpondyloArthritis international Society; **ASDAS**, AS Disease Activity Score; **axSpA**, axial spondyloarthritis; **CRP**, C-reactive protein; **IBP**, inflammatory back pain; **IL**, interleukin; **MRI**, magnetic resonance imaging; **nr-axSpA**, non-radiographic axSpA; **NSAID**, nonsteroidal anti-inflammatory drug; **QoL**, quality of life; **SIJ**, sacroiliac joint.



The Classification and Progression of axSpA

axSpA can be difficult to identify and is often misdiagnosed, but careful evaluation of patients with lower back pain is important to help diagnose and manage the disease as early as possible.¹⁻³




Learn how to **evaluate** your patients with lower back pain, and in those with axSpA, **classify** the spectrum of their disease and **recognize** the impact of disease progression.



ASAS Classification Criteria for axSpA⁴

In patients with ≥ 3 months of chronic back pain and age of onset < 45 years



copyright permissions granted by Spa-Imaging.Org (author Anne Grethe Jurik) for the MRI and X-ray images

The Natural History of axSpA⁵



copyright permissions granted by Spa-Imaging.Org (author Anne Grethe Jurik) for the MRI and X-ray images